News
Viking Therapeutics (VKTX 1.70%) is developing VK2735, a dual GLP-1/GIP receptor agonist for obesity treatment. The company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback